

NCT03589105 Raw comparison:

Summary:
CHIA has 16 criteria while your personal folder has 17 criteria
Total found criteria: 16/16
Total not Found: 0/16
Total Extra: 1
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Age >/=18 years at screening                       │ Age \>/=18 years at screening                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients with relapsing forms of multiple          │ Patients with relapsing forms of multiple          │
│ sclerosis (RMS) with active disease defined by     │ sclerosis (RMS) with active disease defined by     │
│ clinical or imaging features (i) at least one      │ clinical or imaging features (i) at least one      │
│ clinical relapse over a 6-month period prior to    │ clinical relapse over a 6-month period prior to    │
│ screening (ii) AND/OR at least one T1 gadolinium-  │ screening (ii) AND/OR at least one T1 gadolinium-  │
│ enhancing lesion or new and/or enlarging T2 lesion │ enhancing lesion or new and/or enlarging T2 lesion │
│ as detected by brain Magnetic Resonance Imaging    │ as detected by brain Magnetic Resonance Imaging    │
│ (MRI) performed over a 3 months period prior to    │ (MRI) performed over a 3 months period prior to    │
│ screening with no change of Disease-Modifying      │ screening with no change of Disease-Modifying      │
│ Treatment(s) (DMT) compared to a previous MRI      │ Treatment(s) (DMT) compared to a previous MRI      │
│ performed within 24 months before screening        │ performed within 24 months before screening        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ For women of childbearing potential agreement to   │ For women of childbearing potential agreement to   │
│ use an acceptable birth control method during the  │ use an acceptable birth control method during the  │
│ treatment period and for at least 12 months after  │ treatment period and for at least 12 months after  │
│ the last dose of ocrelizumab                       │ the last dose of ocrelizumab                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Participants should be beneficiary of healthcare   │ Participants should be beneficiary of healthcare   │
│ coverage under the social security system          │ coverage under the social security system          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Diagnosis of primary progressive MS                │ Diagnosis of primary progressive MS                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Inability to complete an MRI (contraindications    │ Inability to complete an MRI (contraindications    │
│ for MRI include but are not restricted to weight   │ for MRI include but are not restricted to weight   │
│ =140 kg pacemaker cochlear implants presence of    │ ≥140 kg pacemaker cochlear implants presence of    │
│ foreign substances in the eye intracranial         │ foreign substances in the eye intracranial         │
│ vascular clips surgery within 6 weeks of entry     │ vascular clips surgery within 6 weeks of entry     │
│ into the study coronary stent implanted within 8   │ into the study coronary stent implanted within 8   │
│ weeks prior to the time of the intended MRI etc…)  │ weeks prior to the time of the intended MRI etc )  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Gadolinium intolerance                             │ Gadolinium intolerance                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of ischemic cerebrovascular disorders (e g │ History of ischemic cerebrovascular disorders (e g │
│ stroke transient ischemic attack) or ischemia of   │ stroke transient ischemic attack) or ischemia of   │
│ the spinal cord                                    │ the spinal cord                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History or known presence of central nervous       │ History or known presence of central nervous       │
│ system (CNS) or spinal cord tumor (e g meningioma  │ system (CNS) or spinal cord tumor (e g meningioma  │
│ glioma)                                            │ glioma)                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History or known presence of potential metabolic   │ History or known presence of potential metabolic   │
│ causes of myelopathy (e g untreated vitamin B12    │ causes of myelopathy (e g untreated vitamin B12    │
│ deficiency)                                        │ deficiency)                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History or known presence of infectious causes of  │ History or known presence of infectious causes of  │
│ myelopathy (e g syphilis Lyme disease human        │ myelopathy (e g syphilis Lyme disease human        │
│ T-lymphotropic virus 1 (HTLV-1) herpes zoster      │ T-lymphotropic virus 1 (HTLV-1) herpes zoster      │
│ myelopathy)                                        │ myelopathy)                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of genetically inherited progressive CNS   │ History of genetically inherited progressive CNS   │
│ degenerative disorder (e g hereditary paraparesis  │ degenerative disorder (e g hereditary paraparesis  │
│ MELAS [mitochondrial myopathy encephalopathy       │ MELAS \[mitochondrial myopathy encephalopathy      │
│ lactic acidosis stroke] syndrome)                  │ lactic acidosis stroke\] syndrome)                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Neuromyelitis optica                               │ Neuromyelitis optica                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History or known presence of systemic autoimmune   │ History or known presence of systemic autoimmune   │
│ disorders potentially causing progressive          │ disorders potentially causing progressive          │
│ neurologic disease (e g lupus anti-phospholipid    │ neurologic disease (e g lupus anti-phospholipid    │
│ antibody syndrome Sjogren's syndrome Behçet's      │ antibody syndrome Sjogren's syndrome Behçet's      │
│ disease sarcoidosis)                               │ disease sarcoidosis)                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of severe clinically significant brain or  │ History of severe clinically significant brain or  │
│ spinal cord trauma (e g cerebral contusion spinal  │ spinal cord trauma (e g cerebral contusion spinal  │
│ cord compression)                                  │ cord compression)                                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Vulnerable patients (Patient referred to in        │ Vulnerable patients (Patient referred to in        │
│ Articles L 1121-5 to L 1121-8 and L 1122-1-2 of    │ Articles L 1121-5 to L 1121-8 and L 1122-1-2 of    │
│ the French Public Health Code)                     │ the French Public Health Code)                     │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Must have minimum age of 18 Years │
╘═══════════════════════════════════╛